Lindbrook Capital, LLC Annexon, Inc. Transaction History

Lindbrook Capital, LLC

$1.18 Billion
Q3 2024

A detailed history of Lindbrook Capital, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 83 shares of ANNX stock, worth $548. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$548

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 01, 2024	BUY	$4.49 - $7.2 $372 - $597	83 New	83 $0
Q1 2024 Apr 25, 2024	BUY	$4.03 - $7.81 $1,168 - $2,264	290 New	290 $2,000

Others Institutions Holding ANNX

# of Institutions

158

Shares Held

102M

Call Options Held

3.61M

Put Options Held

1.08M

Bain Capital Life Sciences Investors, LLC Boston, MA

8.45M
Shares

$55.8 Million
8.47% of portfolio
Satter Management Co., L.P.

7.41M
Shares

$49 Million
76.44% of portfolio
Bvf Inc San Francisco, CA

7M
Shares

$46.3 Million
1.05% of portfolio
Black Rock Inc. New York, NY

6.59M
Shares

$43.5 Million
0.0% of portfolio
Redmile Group, LLC San Francisco, CA

6.43M
Shares

$42.5 Million
2.05% of portfolio

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $315M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.

Account